Joel Greenblatt Biocryst Pharmaceuticals Inc Transaction History

Gotham Asset Management, LLC

$9.41 Billion
Q3 2024

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Gotham Asset Management, LLC holds 38,893 shares of BCRX stock, worth $294,420. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,893

Holding current value

$294,420

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $249,304 - $337,980	38,893 New	38,893 $295,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $463,211 - $546,741	69,033 New	69,033 $488,000
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $259,326 - $355,943	24,034 New	24,034 $303,000
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $114,783 - $260,118	-14,548 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $37,454 - $64,022	3,240 Added 28.65%	14,548 $237,000
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $126,423 - $174,821	11,308 New	11,308 $157,000
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $691,188 - $858,513	-48,641 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $462,089 - $838,570	48,641 New	48,641 $769,000
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $108,029 - $199,495	-14,658 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $2,338 - $5,975	694 Added 4.97%	14,658 $109,000
Q3 2020 Nov 16, 2020	SELL	$3.43 - $5.53 $4,033 - $6,503	-1,176 Reduced 7.77%	13,964 $48,000
Q2 2020 Aug 13, 2020	SELL	$1.9 - $5.61 $25,133 - $74,209	-13,228 Reduced 46.63%	15,140 $72,000
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $45,388 - $116,592	28,368 New	28,368 $57,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account